Literature DB >> 25759616

Guideline conformity treatment in young women with early-onset breast cancer in Germany.

Telja Pursche1, Marianne Hedderich1, Alessa Heinrichs1, Kristin Baumann1, Constanze Banz-Jansen1, Achim Rody1, Annika Waldmann2, Dorothea Fischer1.   

Abstract

BACKGROUND: The purpose of the study was to characterize the treatment of young mothers with breast cancer in Germany and to investigate whether it followed applicable guidelines.
METHOD: Retrospective data obtained between 2002 and 2011 for 1,053 mothers with children of < 12 years of age with adjuvantly treated loco-regional primary breast cancer were analyzed. Collected data included sociodemographic data, TNM stage, biology of tumor and therapies. Actually received therapies were compared to those suggested in guideline treatment plans.
RESULTS: The mean age of the patients was 39 years. 97% of the women with node positivity received an axillary dissection. Overall, 90% of the patients received chemotherapy with a guideline adherence range of 87-99% depending on clinical parameters. For radiation therapy, guideline adherence was high (range 82-100%). 95% of the patients with a hormone receptor-positive tumor received endocrine therapy; in 94%, tamoxifen therapy was performed in compliance with guidelines, whereas gonadotropin-releasing hormone (GnRH) agonist therapy complied with the guidelines in 52% of the cases.
CONCLUSION: Guideline adherence in young mothers with breast cancer in Germany was high (with the exception of GnRH therapy), as comorbidity or the ambiguity of the therapeutic success does not need to be considered as much in this young, otherwise usually healthy, cohort compared to an age-heterogeneous group.

Entities:  

Keywords:  Breast cancer; Guideline; Recommendations; Therapy; Young

Year:  2014        PMID: 25759616      PMCID: PMC4322693          DOI: 10.1159/000366435

Source DB:  PubMed          Journal:  Breast Care (Basel)        ISSN: 1661-3791            Impact factor:   2.860


  22 in total

1.  Guideline-compatible treatment of breast cancer patients: the status quo in schleswig-holstein.

Authors:  Annika Waldmann; Ron Pritzkuleit; Heiner Raspe; Alexander Katalinic
Journal:  Dtsch Arztebl Int       Date:  2008-05-02       Impact factor: 5.594

2.  A comparison of international breast cancer guidelines - do the national guidelines differ in treatment recommendations?

Authors:  R Wolters; A C Regierer; L Schwentner; V Geyer; K Possinger; R Kreienberg; M B Wischnewsky; A Wöckel
Journal:  Eur J Cancer       Date:  2011-07-07       Impact factor: 9.162

3.  HER-2/neu oncogene protein and prognosis in breast cancer.

Authors:  A K Tandon; G M Clark; G C Chamness; A Ullrich; W L McGuire
Journal:  J Clin Oncol       Date:  1989-08       Impact factor: 44.544

4.  Epidemiology of Breast Cancer - Current Figures and Trends.

Authors:  N Eisemann; A Waldmann; A Katalinic
Journal:  Geburtshilfe Frauenheilkd       Date:  2013-02       Impact factor: 2.915

5.  Are there changes in characteristics and therapy of young patients with early-onset breast cancer in Germany over the last decade?

Authors:  Constanze Banz-Jansen; Alessa Heinrichs; Marianne Hedderich; Annika Waldmann; Berit Wedel; Imke Mebes; Klaus Diedrich; Achim Rody; Dorothea Fischer
Journal:  Arch Gynecol Obstet       Date:  2013-02-14       Impact factor: 2.344

6.  Pathological prognostic factors in breast cancer. III. Vascular invasion: relationship with recurrence and survival in a large study with long-term follow-up.

Authors:  S E Pinder; I O Ellis; M Galea; S O'Rouke; R W Blamey; C W Elston
Journal:  Histopathology       Date:  1994-01       Impact factor: 5.087

7.  The European Society of Breast Cancer Specialists recommendations for the management of young women with breast cancer.

Authors:  Fatima Cardoso; Sibylle Loibl; Olivia Pagani; Alessandra Graziottin; Pietro Panizza; Laura Martincich; Oreste Gentilini; Fedro Peccatori; Alain Fourquet; Suzette Delaloge; Lorenza Marotti; Frédérique Penault-Llorca; Anna Maria Kotti-Kitromilidou; Alan Rodger; Nadia Harbeck
Journal:  Eur J Cancer       Date:  2012-10-29       Impact factor: 9.162

8.  Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.

Authors:  C Davies; J Godwin; R Gray; M Clarke; D Cutter; S Darby; P McGale; H C Pan; C Taylor; Y C Wang; M Dowsett; J Ingle; R Peto
Journal:  Lancet       Date:  2011-07-28       Impact factor: 79.321

9.  The population-based oncological health care study OVIS - recruitment of the patients and analysis of the non-participants.

Authors:  Ron Pritzkuleit; Annika Waldmann; Heiner Raspe; Alexander Katalinic
Journal:  BMC Cancer       Date:  2008-10-27       Impact factor: 4.430

10.  Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013.

Authors:  A Goldhirsch; E P Winer; A S Coates; R D Gelber; M Piccart-Gebhart; B Thürlimann; H-J Senn
Journal:  Ann Oncol       Date:  2013-08-04       Impact factor: 32.976

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.